Leukemia & Lymphoma Society
First-line regimen improves PFS in chronic lymphocytic leukemia
SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.
AI in hematology: ‘The good, the bad and the ugly’
SAN DIEGO — The increased use of AI in health care has generated tremendous excitement for its potential to guide treatment decision-making, improve outcomes and increase efficiency.
Study yields 'encouraging' preliminary data for navitoclax combination in myelofibrosis
SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.
FDA approves Bosulif for children with chronic myelogenous leukemia
The FDA expanded the approval of bosutinib to include treatment of certain children with chronic myelogenous leukemia.
ASCO studies reveal ‘unprecedented’ benefit with CAR-T as earlier treatment
Now that chimeric antigen receptor T-cell therapy has become part of the treatment landscape in hematologic malignancies, researchers are focused on developing more potent, less toxic agents that can be used in earlier treatment settings.
VIDEO: Importance of increasing CLL awareness
Healio spoke with Ryan. W. Jacobs, MD, about the importance of increasing awareness of CLL in patients, physicians and the general public.